Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241720 (US9409917, 17 | US9409917, 18) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241779 (US9409917, 104 | US9409917, 105 | US9409917, 76 | ...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241725 (US9409917, 22) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241720 (US9409917, 17 | US9409917, 18) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.60 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241706 (US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.80 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241706 (US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.70 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241727 (US9409917, 24 | US9409917, 25) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.70 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241743 (US9409917, 40) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.70 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241706 (US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.90 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241715 (US9409917, 12) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.10 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241782 (US9409917, 79 | US9409917, 80) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.10 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241779 (US9409917, 104 | US9409917, 105 | US9409917, 76 | ...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241714 (US9409917, 11) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241804 (US9409917, 101 | US9409917, 102 | US9409917, 109 |...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241754 (US9409917, 51) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.60 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241722 (US9409917, 19) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.30 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241770 (US9409917, 67) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.30 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241814 (US9409917, 111 | US9409917, 112) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241779 (US9409917, 104 | US9409917, 105 | US9409917, 76 | ...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241737 (US9409917, 34) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10.7 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241804 (US9409917, 101 | US9409917, 102 | US9409917, 109 |...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241796 (US9409917, 93) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11.4 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241742 (US9409917, 39) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11.8 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241726 (US9409917, 23) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12.2 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241817 (US9409917, 114) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241719 (US9409917, 16) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12.6 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241724 (US9409917, 21) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 12.9 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241771 (US9409917, 68) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13.8 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241775 (US9409917, 72) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14.6 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241734 (US9409917, 31) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241744 (US9409917, 41) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16.3 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241706 (US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 18.3 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241706 (US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 20 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241776 (US9409917, 73) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 20.2 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241779 (US9409917, 104 | US9409917, 105 | US9409917, 76 | ...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 20.6 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241762 (US9409917, 59 | US9409917, 60 | US9409917, 81 | US...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 20.8 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241735 (US9409917, 32) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 25 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241729 (US9409917, 26) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 25.6 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241757 (US9409917, 54) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 25.8 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241762 (US9409917, 59 | US9409917, 60 | US9409917, 81 | US...) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 29 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241777 (US9409917, 74 | US9409917, 75) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 35.3 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241818 (US9409917, 115) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 35.4 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241816 (US9409917, 113) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 35.9 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241773 (US9409917, 70 | US9409917, 71) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 36.5 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241748 (US9409917, 45) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 37.2 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241727 (US9409917, 24 | US9409917, 25) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 39.4 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241758 (US9409917, 55) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 41.6 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241745 (US9409917, 42) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 46.9 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241765 (US9409917, 62) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 46.9 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
P2X purinoceptor 7 (Homo sapiens (Human)) | BDBM241782 (US9409917, 79 | US9409917, 80) | PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 51.1 | n/a | n/a | n/a | n/a | n/a | 37 |
ACTELION PHARMACEUTICALS LTD. US Patent | Assay Description HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ... | US Patent US9409917 (2016) BindingDB Entry DOI: 10.7270/Q2ZS2VC8 | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 118 total ) | Next | Last >> |